Cancer Cell International (Aug 2023)

Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma

  • Fanxuan Huang,
  • Xinyu Wang,
  • Junzhe Zhong,
  • Hao Chen,
  • Dan Song,
  • Tianye Xu,
  • Kaifu Tian,
  • Penggang Sun,
  • Nan Sun,
  • Jie Qin,
  • Yu Song,
  • Wenbin Ma,
  • Yuxiang Liu,
  • Daohan Yu,
  • Xiangqi Meng,
  • Chuanlu Jiang,
  • Hanwen Xuan,
  • Da Qian,
  • Jinquan Cai

DOI
https://doi.org/10.1186/s12935-023-03001-w
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Background N6-methyladenosine (m6A), 5-methylcytosine (m5C) and N1-methyladenosine (m1A) are the main RNA methylation modifications involved in the progression of cancer. However, it is still unclear whether RNA methylation-related long noncoding RNAs (lncRNAs) affect the prognosis of glioma. Methods We summarized 32 m6A/m5C/m1A-related genes and downloaded RNA-seq data and clinical information from The Cancer Genome Atlas (TCGA) database. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were used to identify differentially expressed (DE-) RNA methylation-related lncRNAs in order to construct a prognostic signature of glioma and in order to determine their correlation with immune function, immune therapy and drug sensitivity. In vitro and in vivo assays were performed to elucidate the effects of RNA methylation-related lncRNAs on glioma. Results A total of ten RNA methylation-related lncRNAs were used to construct a survival and prognosis signature, which had good independent prediction ability for patients. It was found that the high-risk group had worse overall survival (OS) than the low-risk group in all cohorts. In addition, the risk group informed the immune function, immunotherapy response and drug sensitivity of patients with glioma in different subgroups. Knockdown of RP11-98I9.4 and RP11-752G15.8 induced a more invasive phenotype, accelerated cell growth and apparent resistance to temozolomide (TMZ) both in vitro and in vivo. We observed significantly elevated global RNA m5C and m6A levels in glioma cells. Conclusion Our study determined the prognostic implication of RNA methylation-related lncRNAs in gliomas, established an RNA methylation-related lncRNA prognostic model, and elucidated that RP11-98I9.4 and RP11-752G15.8 could suppress glioma proliferation, migration and TMZ resistance. In the future, these RNA methylation-related lncRNAs may become a new choice for immunotherapy of glioma.

Keywords